Summary

The global Tumor Necrosis Factor Inhibitors Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Tumor Necrosis Factor Inhibitors Drug Industry Forecast” looks at past sales and reviews total world Tumor Necrosis Factor Inhibitors Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Tumor Necrosis Factor Inhibitors Drug sales for 2025 through 2031. With Tumor Necrosis Factor Inhibitors Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Necrosis Factor Inhibitors Drug industry.
This Insight Report provides a comprehensive analysis of the global Tumor Necrosis Factor Inhibitors Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Necrosis Factor Inhibitors Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Necrosis Factor Inhibitors Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Necrosis Factor Inhibitors Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Necrosis Factor Inhibitors Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Necrosis Factor Inhibitors Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Cimzia (Certolizumab Pegol)
Enbrel (Etanercept)
Humira ( Adalimumab)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
Segmentation by Application:
Clinic
Hospital
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Apogenix
AryoGen Biopharma
Bionovis
CASI Pharmaceuticals
Celltrion
Celgene Corporation
Delenex Therapeutics
Dexa Medica
EPIRUS Biopharmaceuticals
Janssen Biotech
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
LG Life Sciences
MedImmune
Momenta Pharmaceuticals
Novartis
PROBIOMED
Reliance Life Sciences
Sandoz
Samsung Bioepis
Sanofi-Aventis
Shanghai CP Guojian Pharmaceutical
Shanghai Pharmaceuticals
Simcere Pharmaceutical
Toyama Chemical
Tsumura
UCB
Zydus Cadila
Key Questions Addressed in this Report
What is the 10-year outlook for the global Tumor Necrosis Factor Inhibitors Drug market?
What factors are driving Tumor Necrosis Factor Inhibitors Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Tumor Necrosis Factor Inhibitors Drug market opportunities vary by end market size?
How does Tumor Necrosis Factor Inhibitors Drug break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Tumor Necrosis Factor Inhibitors Drug by Country/Region, 2020, 2024 & 2031
2.2 Tumor Necrosis Factor Inhibitors Drug Segment by Type
2.2.1 Cimzia (Certolizumab Pegol)
2.2.2 Enbrel (Etanercept)
2.2.3 Humira ( Adalimumab)
2.2.4 Otezla (Apremilast)
2.2.5 Remicade (Infliximab)
2.2.6 Simponi (Golimumab)
2.3 Tumor Necrosis Factor Inhibitors Drug Sales by Type
2.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Type (2020-2025)
2.4 Tumor Necrosis Factor Inhibitors Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Tumor Necrosis Factor Inhibitors Drug Sales by Application
2.5.1 Global Tumor Necrosis Factor Inhibitors Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Tumor Necrosis Factor Inhibitors Drug Breakdown Data by Company
3.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Company (2020-2025)
3.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2020-2025)
3.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2020-2025)
3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2020-2025)
3.3 Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Company
3.4 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Location Distribution
3.4.2 Players Tumor Necrosis Factor Inhibitors Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Tumor Necrosis Factor Inhibitors Drug by Geographic Region
4.1 World Historic Tumor Necrosis Factor Inhibitors Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Tumor Necrosis Factor Inhibitors Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Tumor Necrosis Factor Inhibitors Drug Sales Growth
4.4 APAC Tumor Necrosis Factor Inhibitors Drug Sales Growth
4.5 Europe Tumor Necrosis Factor Inhibitors Drug Sales Growth
4.6 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Growth
5 Americas
5.1 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country
5.1.1 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025)
5.1.2 Americas Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2020-2025)
5.2 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025)
5.3 Americas Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region
6.1.1 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region (2020-2025)
6.1.2 APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2020-2025)
6.2 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025)
6.3 APAC Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors Drug by Country
7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025)
7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2020-2025)
7.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025)
7.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug by Country
8.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors Drug
10.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
10.4 Industry Chain Structure of Tumor Necrosis Factor Inhibitors Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Necrosis Factor Inhibitors Drug Distributors
11.3 Tumor Necrosis Factor Inhibitors Drug Customer
12 World Forecast Review for Tumor Necrosis Factor Inhibitors Drug by Geographic Region
12.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Forecast by Region
12.1.1 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Region (2026-2031)
12.1.2 Global Tumor Necrosis Factor Inhibitors Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Type (2026-2031)
12.7 Global Tumor Necrosis Factor Inhibitors Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Apogenix
13.1.1 Apogenix Company Information
13.1.2 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Apogenix Main Business Overview
13.1.5 Apogenix Latest Developments
13.2 AryoGen Biopharma
13.2.1 AryoGen Biopharma Company Information
13.2.2 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AryoGen Biopharma Main Business Overview
13.2.5 AryoGen Biopharma Latest Developments
13.3 Bionovis
13.3.1 Bionovis Company Information
13.3.2 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Bionovis Main Business Overview
13.3.5 Bionovis Latest Developments
13.4 CASI Pharmaceuticals
13.4.1 CASI Pharmaceuticals Company Information
13.4.2 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 CASI Pharmaceuticals Main Business Overview
13.4.5 CASI Pharmaceuticals Latest Developments
13.5 Celltrion
13.5.1 Celltrion Company Information
13.5.2 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Celltrion Main Business Overview
13.5.5 Celltrion Latest Developments
13.6 Celgene Corporation
13.6.1 Celgene Corporation Company Information
13.6.2 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Celgene Corporation Main Business Overview
13.6.5 Celgene Corporation Latest Developments
13.7 Delenex Therapeutics
13.7.1 Delenex Therapeutics Company Information
13.7.2 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Delenex Therapeutics Main Business Overview
13.7.5 Delenex Therapeutics Latest Developments
13.8 Dexa Medica
13.8.1 Dexa Medica Company Information
13.8.2 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Dexa Medica Main Business Overview
13.8.5 Dexa Medica Latest Developments
13.9 EPIRUS Biopharmaceuticals
13.9.1 EPIRUS Biopharmaceuticals Company Information
13.9.2 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 EPIRUS Biopharmaceuticals Main Business Overview
13.9.5 EPIRUS Biopharmaceuticals Latest Developments
13.10 Janssen Biotech
13.10.1 Janssen Biotech Company Information
13.10.2 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Janssen Biotech Main Business Overview
13.10.5 Janssen Biotech Latest Developments
13.11 GlaxoSmithKline
13.11.1 GlaxoSmithKline Company Information
13.11.2 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 GlaxoSmithKline Main Business Overview
13.11.5 GlaxoSmithKline Latest Developments
13.12 HanAll Biopharma
13.12.1 HanAll Biopharma Company Information
13.12.2 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 HanAll Biopharma Main Business Overview
13.12.5 HanAll Biopharma Latest Developments
13.13 Intas Pharmaceuticals
13.13.1 Intas Pharmaceuticals Company Information
13.13.2 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Intas Pharmaceuticals Main Business Overview
13.13.5 Intas Pharmaceuticals Latest Developments
13.14 LEO Pharma
13.14.1 LEO Pharma Company Information
13.14.2 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 LEO Pharma Main Business Overview
13.14.5 LEO Pharma Latest Developments
13.15 LG Life Sciences
13.15.1 LG Life Sciences Company Information
13.15.2 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 LG Life Sciences Main Business Overview
13.15.5 LG Life Sciences Latest Developments
13.16 MedImmune
13.16.1 MedImmune Company Information
13.16.2 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 MedImmune Main Business Overview
13.16.5 MedImmune Latest Developments
13.17 Momenta Pharmaceuticals
13.17.1 Momenta Pharmaceuticals Company Information
13.17.2 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Momenta Pharmaceuticals Main Business Overview
13.17.5 Momenta Pharmaceuticals Latest Developments
13.18 Novartis
13.18.1 Novartis Company Information
13.18.2 Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Novartis Main Business Overview
13.18.5 Novartis Latest Developments
13.19 PROBIOMED
13.19.1 PROBIOMED Company Information
13.19.2 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 PROBIOMED Main Business Overview
13.19.5 PROBIOMED Latest Developments
13.20 Reliance Life Sciences
13.20.1 Reliance Life Sciences Company Information
13.20.2 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Reliance Life Sciences Main Business Overview
13.20.5 Reliance Life Sciences Latest Developments
13.21 Sandoz
13.21.1 Sandoz Company Information
13.21.2 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Sandoz Main Business Overview
13.21.5 Sandoz Latest Developments
13.22 Samsung Bioepis
13.22.1 Samsung Bioepis Company Information
13.22.2 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Samsung Bioepis Main Business Overview
13.22.5 Samsung Bioepis Latest Developments
13.23 Sanofi-Aventis
13.23.1 Sanofi-Aventis Company Information
13.23.2 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Sanofi-Aventis Main Business Overview
13.23.5 Sanofi-Aventis Latest Developments
13.24 Shanghai CP Guojian Pharmaceutical
13.24.1 Shanghai CP Guojian Pharmaceutical Company Information
13.24.2 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Shanghai CP Guojian Pharmaceutical Main Business Overview
13.24.5 Shanghai CP Guojian Pharmaceutical Latest Developments
13.25 Shanghai Pharmaceuticals
13.25.1 Shanghai Pharmaceuticals Company Information
13.25.2 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 Shanghai Pharmaceuticals Main Business Overview
13.25.5 Shanghai Pharmaceuticals Latest Developments
13.26 Simcere Pharmaceutical
13.26.1 Simcere Pharmaceutical Company Information
13.26.2 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.26.4 Simcere Pharmaceutical Main Business Overview
13.26.5 Simcere Pharmaceutical Latest Developments
13.27 Toyama Chemical
13.27.1 Toyama Chemical Company Information
13.27.2 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.27.4 Toyama Chemical Main Business Overview
13.27.5 Toyama Chemical Latest Developments
13.28 Tsumura
13.28.1 Tsumura Company Information
13.28.2 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.28.4 Tsumura Main Business Overview
13.28.5 Tsumura Latest Developments
13.29 UCB
13.29.1 UCB Company Information
13.29.2 UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.29.4 UCB Main Business Overview
13.29.5 UCB Latest Developments
13.30 Zydus Cadila
13.30.1 Zydus Cadila Company Information
13.30.2 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
13.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.30.4 Zydus Cadila Main Business Overview
13.30.5 Zydus Cadila Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Tumor Necrosis Factor Inhibitors Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Tumor Necrosis Factor Inhibitors Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cimzia (Certolizumab Pegol)
Table 4. Major Players of Enbrel (Etanercept)
Table 5. Major Players of Humira ( Adalimumab)
Table 6. Major Players of Otezla (Apremilast)
Table 7. Major Players of Remicade (Infliximab)
Table 8. Major Players of Simponi (Golimumab)
Table 9. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025) & (K Pcs)
Table 10. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
Table 11. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2020-2025) & ($ million)
Table 12. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2020-2025)
Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 14. Global Tumor Necrosis Factor Inhibitors Drug Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Tumor Necrosis Factor Inhibitors Drug Sale Market Share by Application (2020-2025)
Table 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2020-2025) & ($ million)
Table 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2020-2025)
Table 18. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Tumor Necrosis Factor Inhibitors Drug Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2020-2025)
Table 21. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2020-2025)
Table 23. Global Tumor Necrosis Factor Inhibitors Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Tumor Necrosis Factor Inhibitors Drug Producing Area Distribution and Sales Area
Table 25. Players Tumor Necrosis Factor Inhibitors Drug Products Offered
Table 26. Tumor Necrosis Factor Inhibitors Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Tumor Necrosis Factor Inhibitors Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Geographic Region (2020-2025)
Table 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Tumor Necrosis Factor Inhibitors Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country/Region (2020-2025)
Table 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2020-2025)
Table 39. Americas Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025) & (K Pcs)
Table 41. Americas Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2020-2025)
Table 44. APAC Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025) & (K Pcs)
Table 46. APAC Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025) & (K Pcs)
Table 50. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Tumor Necrosis Factor Inhibitors Drug
Table 56. Key Market Challenges & Risks of Tumor Necrosis Factor Inhibitors Drug
Table 57. Key Industry Trends of Tumor Necrosis Factor Inhibitors Drug
Table 58. Tumor Necrosis Factor Inhibitors Drug Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Tumor Necrosis Factor Inhibitors Drug Distributors List
Table 61. Tumor Necrosis Factor Inhibitors Drug Customer List
Table 62. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Tumor Necrosis Factor Inhibitors Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Tumor Necrosis Factor Inhibitors Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 73. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 75. Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. Apogenix Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 77. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 78. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. Apogenix Main Business
Table 80. Apogenix Latest Developments
Table 81. AryoGen Biopharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 83. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. AryoGen Biopharma Main Business
Table 85. AryoGen Biopharma Latest Developments
Table 86. Bionovis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 88. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Bionovis Main Business
Table 90. Bionovis Latest Developments
Table 91. CASI Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 93. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. CASI Pharmaceuticals Main Business
Table 95. CASI Pharmaceuticals Latest Developments
Table 96. Celltrion Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 98. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99. Celltrion Main Business
Table 100. Celltrion Latest Developments
Table 101. Celgene Corporation Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 103. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Celgene Corporation Main Business
Table 105. Celgene Corporation Latest Developments
Table 106. Delenex Therapeutics Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 108. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Delenex Therapeutics Main Business
Table 110. Delenex Therapeutics Latest Developments
Table 111. Dexa Medica Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 113. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. Dexa Medica Main Business
Table 115. Dexa Medica Latest Developments
Table 116. EPIRUS Biopharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 118. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. EPIRUS Biopharmaceuticals Main Business
Table 120. EPIRUS Biopharmaceuticals Latest Developments
Table 121. Janssen Biotech Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 123. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Janssen Biotech Main Business
Table 125. Janssen Biotech Latest Developments
Table 126. GlaxoSmithKline Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 128. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. GlaxoSmithKline Main Business
Table 130. GlaxoSmithKline Latest Developments
Table 131. HanAll Biopharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 133. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. HanAll Biopharma Main Business
Table 135. HanAll Biopharma Latest Developments
Table 136. Intas Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 138. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. Intas Pharmaceuticals Main Business
Table 140. Intas Pharmaceuticals Latest Developments
Table 141. LEO Pharma Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 143. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. LEO Pharma Main Business
Table 145. LEO Pharma Latest Developments
Table 146. LG Life Sciences Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 148. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. LG Life Sciences Main Business
Table 150. LG Life Sciences Latest Developments
Table 151. MedImmune Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 153. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. MedImmune Main Business
Table 155. MedImmune Latest Developments
Table 156. Momenta Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 158. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. Momenta Pharmaceuticals Main Business
Table 160. Momenta Pharmaceuticals Latest Developments
Table 161. Novartis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 162. Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 163. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 164. Novartis Main Business
Table 165. Novartis Latest Developments
Table 166. PROBIOMED Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 167. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 168. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 169. PROBIOMED Main Business
Table 170. PROBIOMED Latest Developments
Table 171. Reliance Life Sciences Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 172. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 173. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 174. Reliance Life Sciences Main Business
Table 175. Reliance Life Sciences Latest Developments
Table 176. Sandoz Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 177. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 178. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 179. Sandoz Main Business
Table 180. Sandoz Latest Developments
Table 181. Samsung Bioepis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 182. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 183. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 184. Samsung Bioepis Main Business
Table 185. Samsung Bioepis Latest Developments
Table 186. Sanofi-Aventis Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 187. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 188. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 189. Sanofi-Aventis Main Business
Table 190. Sanofi-Aventis Latest Developments
Table 191. Shanghai CP Guojian Pharmaceutical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 192. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 193. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 194. Shanghai CP Guojian Pharmaceutical Main Business
Table 195. Shanghai CP Guojian Pharmaceutical Latest Developments
Table 196. Shanghai Pharmaceuticals Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 197. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 198. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 199. Shanghai Pharmaceuticals Main Business
Table 200. Shanghai Pharmaceuticals Latest Developments
Table 201. Simcere Pharmaceutical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 202. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 203. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 204. Simcere Pharmaceutical Main Business
Table 205. Simcere Pharmaceutical Latest Developments
Table 206. Toyama Chemical Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 207. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 208. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 209. Toyama Chemical Main Business
Table 210. Toyama Chemical Latest Developments
Table 211. Tsumura Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 212. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 213. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 214. Tsumura Main Business
Table 215. Tsumura Latest Developments
Table 216. UCB Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 217. UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 218. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 219. UCB Main Business
Table 220. UCB Latest Developments
Table 221. Zydus Cadila Basic Information, Tumor Necrosis Factor Inhibitors Drug Manufacturing Base, Sales Area and Its Competitors
Table 222. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolios and Specifications
Table 223. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 224. Zydus Cadila Main Business
Table 225. Zydus Cadila Latest Developments


List of Figures
Figure 1. Picture of Tumor Necrosis Factor Inhibitors Drug
Figure 2. Tumor Necrosis Factor Inhibitors Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Tumor Necrosis Factor Inhibitors Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country/Region (2024)
Figure 10. Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Cimzia (Certolizumab Pegol)
Figure 12. Product Picture of Enbrel (Etanercept)
Figure 13. Product Picture of Humira ( Adalimumab)
Figure 14. Product Picture of Otezla (Apremilast)
Figure 15. Product Picture of Remicade (Infliximab)
Figure 16. Product Picture of Simponi (Golimumab)
Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2025
Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2020-2025)
Figure 19. Tumor Necrosis Factor Inhibitors Drug Consumed in Clinic
Figure 20. Global Tumor Necrosis Factor Inhibitors Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 21. Tumor Necrosis Factor Inhibitors Drug Consumed in Hospital
Figure 22. Global Tumor Necrosis Factor Inhibitors Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 23. Tumor Necrosis Factor Inhibitors Drug Consumed in Others
Figure 24. Global Tumor Necrosis Factor Inhibitors Drug Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Tumor Necrosis Factor Inhibitors Drug Sale Market Share by Application (2024)
Figure 26. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application in 2025
Figure 27. Tumor Necrosis Factor Inhibitors Drug Sales by Company in 2025 (K Pcs)
Figure 28. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company in 2025
Figure 29. Tumor Necrosis Factor Inhibitors Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company in 2025
Figure 31. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Tumor Necrosis Factor Inhibitors Drug Sales 2020-2025 (K Pcs)
Figure 34. Americas Tumor Necrosis Factor Inhibitors Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Tumor Necrosis Factor Inhibitors Drug Sales 2020-2025 (K Pcs)
Figure 36. APAC Tumor Necrosis Factor Inhibitors Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Tumor Necrosis Factor Inhibitors Drug Sales 2020-2025 (K Pcs)
Figure 38. Europe Tumor Necrosis Factor Inhibitors Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2025
Figure 42. Americas Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region in 2025
Figure 50. APAC Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2020-2025)
Figure 53. China Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country in 2025
Figure 61. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Tumor Necrosis Factor Inhibitors Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Inhibitors Drug in 2025
Figure 78. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
Figure 79. Industry Chain Structure of Tumor Necrosis Factor Inhibitors Drug
Figure 80. Channels of Distribution
Figure 81. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share Forecast by Application (2026-2031)